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Dithiiranylmethyloxy azaxanthone (CHO10), which was discovered by screening compounds in a repor-
ter gene assay, inhibited the ESX–Sur2 interaction in a dose-dependent manner with potency similar to
canertinib. The intervention of CHO10 during the ESX–Sur2 interaction caused down-regulation of both
HER2 gene ampliﬁcation and HER2 protein expression, which led to the attenuation of HER2-mediated
downstream signal cascades and autocrine cell growth in SK-BR-3 cells, which are HER2 overexpressing
breast cancer cells. The cell growth inhibitory activity of CHO10 was more potent in HER2-overexpressing
breast cancer cells (AU-565, BT474 and SK-BR-3) than in HER2-negative cells (HEK293) and breast cancer
cells (MCF-7) that express a basal level of HER2. Treatment with CHO10 in combination with tamoxifen
sensitized BT474 cells, tamoxifen-resistant ER-positive breast cancer cell line, toward chemotherapeutic.
The anti-tumor activity of CHO10 was validated by the signiﬁcant reduction in tumor size of NCI-H460 or
DLD-1 subcutaneously implanted xenograft tumors through treatment with 1 mg/kg ﬁve times every
other 2 days.
 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Estrogen receptor (ER) is overexpressed in more than 60% of hu-
man breast cancers. These ER-positive cancer patients are com-
monly treated with an anti-estrogenic therapy such as tamoxifen
(TAM) (Kim et al., 2011). Unfortunately, 30% of the ER-positive can-
cer patients who had received TAM treatment did not show
improvement and died from the disease (Early Breast Cancer Trial-
ists, 2005; Chang, 2012). The mechanism underlying the acquisi-
tion of TAM resistance in ER-positive breast cancer has been of
great interest to many investigators. The proposed mechanisms
to date include the loss of ERa expression (Riggins et al., 2007), a
mutation in the ERa (Zhang et al., 1997), higher expression of
ERb than ERa (Speirs et al., 1999), variations in the CYP2D6 genethat cause lower plasma concentrations of effective TAM metabo-
lites (Stearns et al., 2003), overexpression of an ER co-activator,
ampliﬁed in breast cancer 1 (AIB1), which is also known as a ste-
roid receptor co-activator 3 (SRC3) (Osborne et al., 2003; Zhao
et al., 2009; Zwart et al., 2011), reduction of co-repressor, NcoR,
activity (Lavinsky et al., 1998) and the inﬂuences of cellular kinase
signal transduction pathways through cross-talk between ER and
epidermal growth factor receptor (EGFR)/human epidermal growth
factor receptor 2 (HER2)/insulin-like growth factor receptor (IGFR)
(Ring and Dowsett, 2004). Among the reported mechanisms under-
lying the acquisition of TAM resistance, HER2 overexpression-re-
lated mechanisms are summarized as follows. AIB1 is
functionally activated by mitogen-activated protein kinase
(MAPK), the activation of which is induced by HER2 signaling in tu-
mors (Osborne et al., 2003; Hurtado et al., 2008). HER2-mediated
activation of MAPK induces phosphorylation of the serine118 res-
idue in the AF-1 region of ER, which results in ligand-independent
constitutive activation of ER (Bunone et al., 1996). Experimental
evidence showed that HER2 overexpression may be the primary
mechanism of TAM resistance; when HER2-transfected MCF-7
breast cancer cells were implanted into ovariectomized nude mice,
tumor growth continued during TAM treatment (Benz et al., 1993).
In mice carrying xenograft tumors composed of HER2-overexpress-
182 J.M. Nam et al. / European Journal of Pharmaceutical Sciences 50 (2013) 181–190ing MCF-7 cells, tumor growth was stimulated by tamoxifen treat-
ment (Arpino et al., 2007). Clinical studies also showed that the re-
sponse rate to TAM was reduced from 50% in ER-positive cases
with normal HER2 expression to 17% in ER-positive cases with
HER2 overexpression (Chung et al., 2002).
The HER2 transmembrane protein (185 kDa), which is encoded
by the HER2 gene, consists of an extracellular domain for homo-
and hetero-dimerization at the N-terminus, a single membrane
spanning region and an intracellular domain for tyrosine kinase
activity at the C-terminus (Klapper et al., 1999). HER2 is considered
to be an orphan receptor, unlike other HER family members, be-
cause HER2 is activated without binding a ligand. HER2 is favored
as a dimerization partner within the HER family. HER2 dimeriza-
tion results in autophosphorylation of the intracellular tyrosine ki-
nase domain and regulates cell growth, differentiation and
potentiation of intracellular signaling mainly for the initiation of
cancer formation (Carpenter and Cohen, 1990). The determinant
for the HER2 homo- or hetero-dimerization process with other
HER family members is HER2 overexpression (Tzahar et al.,
1996). Breast cancer cells that overexpress epithelial-speciﬁc ETS
transcription factor (ESX/ESE-1/Elf-3) exhibited HER2 gene ampli-N
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Fig. 1. Structures of CHO3 and 10 and their effects on the ESX–Sur2 interaction, HER2 ex
Results of the SEAP assay. CHO10 and canertinib impaired the ability of the ESX activati
cells at 3 lM treatment, whereas CHO3 had a negligible effect on transcriptional activat
inhibitor, is used as a positive control. (C) Effects of compounds on the HER2 mRNA
quantitative RT-PCR method after each compound was administered at a concentration o
after the treatment of each compound at 10 lM for 8 or 16 h. CHO10 remarkably reduce
and demonstrated a potency similar to canertinib. (D) The effects of compounds on HER2
exhibited decreased protein levels of phospho-MAPK and phospho-Akt with a potency si
blocked by CHO10 treatment. The levels of all proteins in (C) and (D) were normalize
depicted as histograms. Values represent the mean ± SD.ﬁcation (Eckel et al., 2003; Schedin et al., 2004). HER2 overexpres-
sion requires the binding of ESX to the HER2 promoter (Chang
et al., 1997) in addition to the binding of DRIP130/Sur2, a meta-
zoan-speciﬁc subunit of the human mediator complex, to the
transactivation domain of ESX (Asada et al., 2002). The 8 amino
acid helical region of ESX mediates its interaction with Sur2; dur-
ing this process, small organic molecules may interfere with the
ESX–Sur2 interaction (Asada et al., 2003). The small molecules re-
ported previously to suppress HER2 expression include adamano-
lol (Asada et al., 2003), wrenchnolol (Shimogawa et al., 2004),
amphipathic isoxazolidine (Lee et al., 2009) and ﬂuoroquinophe-
noxazine derivatives (Kim et al., 2012). In the present study, we fo-
cused on the development of small molecules that were able to
down-regulate HER2 expression via inhibition of the ESX–Sur2
interaction. We found that CHO10, a dithiiranylmethyloxy azax-
anthone derivative (Fig. 1A), potently inhibited the ESX–Sur2 inter-
action, which caused the down-regulation of HER2 expression,
inhibition of the HER2-mediated signal pathway and apoptosis in
HER2-overexpressing breast cancer cells. The inhibitory activity
of CHO10 against the HER2-mediated signal pathway sensitized
TAM-resistant cancer cells to TAM.C
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pression and HER2-mediated signaling cascades. (A) Structures of CHO3 and 10. (B)
on domain to activate the secreted alkaline phosphatase reporter gene in HEK293T
ion when using the same concentration treatment. Canertinib, which is a pan-HER
level and HER2 protein expression. The HER2 mRNA level was evaluated with a
f 10 lM for 8 or 16 h. Western blot analysis of the SK-BR-3 cells was also performed
d HER2 gene ampliﬁcation and protein expression after a 10 lM treatment for 16 h
downstream molecular changes. Western blot analysis was performed as in (C) and
milar to canertinib, which indicated that HER2-mediated downstream signaling was
d to the a-tubulin content of compound-treated or -untreated cells (control) and
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2.1. Antibodies and reagents
HER2, Phospho-HER2 (Tyr877), Phospho-HER2 (Tyr1221/1222),
Phospho-HER2 (Tyr1248), EGFR, Phospho-EGFR (Tyr1068), MAPK
(Erk1/2), Phospho-p44/42 MAPK (Erk1/2) (Thr202/Thr204), Akt,
Phospho-Akt (Ser473), caspase-3, PARP, a-tubulin and Anti-IgG
secondary antibody were purchased from Cell Signaling Technol-
ogy Inc. (Danvers, MA, USA). The 63 synthetic compounds that
were used in the screen for inhibitors of the ESX–Sur2 interaction
were provided by Professor Younghwa Na (College of Pharmacy,
Cha University). These compounds have diverse core structures
and include the following: 9 3-(30-heteroatom substituted-20-hy-
droxy-10-propyloxy) xanthone analogues; 13 2,5,7-heteroatom
substituted chroman-4-one analogues; 13 benzosanthen-12-one
derivatives; 12 4-hydroxy-20-nitrodiphenyl ether analogues; 9
methyloxiranylmethoxyxanthone analogues; and 7 ﬂuoroquin-
ophenoxazine derivatives. Adriamycin, etoposide, camptothecin,
canertinib and BMS599626 were purchased from Sigma–Aldrich
(St. Louis, USA). Wrenchnolol was provided by Professor Uesugi
(Kyoto University, Japan). All of the compounds used in the present
study were dissolved in dimethylsulfoxide (DMSO; Sigma–Aldrich,
St. Louis, USA) to form 10 mM stock solutions and stored at 20 C
until needed.
2.2. Cell lines and cell cultures
Human breast cancer cell lines (MCF-7, MDA-MB231, T47D, SK-
BR-3) and a human kidney cell line (HEK293) were purchased from
the Korean Cell Line Bank (Seoul, Korea). AU-565 (human breast
adenocarcinoma cell line) and MDA-MB468 (human breast cancer
cell line) were kind gifts from Dr. Seung Bae Rho (National Cancer
Center, Korea) and Dr. Yung-Jue Bang (College of Medicine, Seoul
National University, Korea). All cell lines except HEK293 were
maintained in Roswell Park Memorial Institute Medium (RPMI
1640, WelGENE Inc., Daegu, Korea) that was supplemented with
10% fetal bovine serum (FBS, WelGENE Inc. Daegu, Korea) and 1%
penicillin–streptomycin (Hyclone laboratories Inc., Rockford, IL,
USA). HEK293 was cultured in Dulbecco’s Modiﬁed Eagle Medium
(DMEM, WelGENE Inc., Korea) with 10% FBS and 1% penicillin–
streptomycin. These cells were grown at 37 C in a humidiﬁed
atmosphere containing 5% CO2.
2.3. Cell proliferation inhibition assay
The cells were seeded in 96-well microplates at a density of
1–2  104 cells per well and incubated overnight in 0.1 mL of med-
ium supplemented with 10% FBS and 1% penicillin–streptomycin at
37 C in a 5% CO2 incubator. On day 2, after 4 h of FBS depletion, the
compounds were treated by exchanging the media with 0.1 mL ali-
quots of medium containing graded concentrations (0, 0.1, 0.25,
0.5, 1, 2 and 5 lM as a ﬁnal concentration). After 48 h of treatment,
5 lL of cell counting kit-8 (Dojindo, Kumamoto, Japan) was added
to each well followed by an additional 4 h of incubation under the
same conditions. The absorbance of each well was determined
using an Automatic Elisa Reader System (Bio-Rad 3550, Ramsey,
MN, USA) at a wavelength of 450 nm. The viability of cells treated
with CHO10 was calculated from the absorbance, with untreated
cells assumed to be 100% viable.
2.4. Western blot analysis
The cells were seeded in 60 mm dishes at a density of 5  105
cells per dish and incubated until the cells reached a conﬂuenceof 80%. The cells were then washed with FBS-free medium and
incubated for 4 h in FBS-free medium, which was followed by
treatment with the compounds at the concentrations indicated in
the ﬁgure legends. The cells were washed with ice-cold phos-
phate-buffered saline (PBS), detached with 0.25% trypsin-1 mM
EDTA and harvested by centrifugation at 2000 rpm for 3 min. The
cell pellet was resuspended in lysis buffer (50 mM Tris–HCl solu-
tion (pH 8.0) containing 150 mM NaCl, 0.1% SDS, 0.5% sodium
deoxycholate, 1% NP-40, 100 lg/mL phenylmethanesulfonyl ﬂuo-
ride (PMSF) and 1% protease inhibitor cocktail) on ice for 20 min.
Then the cell lysates were centrifuged at 14,000 rpm at 4 C for
20 min. The supernatant was kept at 20 C until use. The amount
of total protein was measured with a BCA™ Protein Assay Kit
(Pierce, Rockford, IL, USA) to normalize the untreated (control)
and treated cell lysates for each compound. The same amount of
each normalized sample underwent electrophoresis on a 12% SDS
polyacrylamide gel, which was then transferred to a polyvinylid-
eneﬂuoride transfer membrane (Miillipore, Billerica, MA, USA) at
150 mA for 90 min. The membrane was blocked with 5% skim milk
in PBS containing 0.05% Tween 20 (TBST) for 1 h, followed by three
washes with TBST. The membrane was then incubated overnight
with a primary antibody at a ratio of 1:1000 at 4 C. The membrane
was washed three times with TBST and incubated with a secondary
antibody at a ratio of 1:2000 for 1 h at room temperature. The
membrane was then washed three times with TBST before the
PowerOpti-ECL (enhanced chemiluminescence, Animal Genetics
Inc., Suwon-si, Korea) western blotting detection reagent was
added, which was then measured with a LAS-3000 (Fuji photo ﬁlm
CO, Ltd., Tokyo, Japan).
2.5. Reverse transcription-PCR analysis
To analyze the effect of the compounds on the gene expression
level, the cells were washed with FBS-free medium and treated
with each compound at the concentrations indicated in the ﬁgure
legends and then washed two times with PBS. Total RNA was ex-
tracted from the cells with an RNeasy Mini Kit (Qiagen, Hilden,
Germany) following the supplier’s instructions. cDNA was synthe-
sized from the extracted RNA through the following method: the
addition of 4 lL of 5 RT buffer, 2 lL of 2.5 mM dNTP, 2 lL of ran-
dom primer (0.1 lg/lL), 0.5 lL of RNase inhibitor (Promega Corp.
Madison, WI, USA), 0.25 lL of M-MLV reverse transcriptase (Pro-
mega Corp. Madison, WI, USA) and 0.5 lg of the extracted RNA
and then incubation at 25 C for 10 min, followed by incubation
at 42 C for 1 h and an additional incubation at 99 C for 5 min.
The synthesized cDNA was stored at 70 C until use. Each synthe-
sized DNA was ampliﬁed using PCR with the following PCR cock-
tail: the addition of 38.5 lL of distilled water, 5 lL of 10
reaction buffer, 3 lL of 10 mM dNTP, 0.5 lL of Taq DNA polymer-
ase, 2 lL of cDNA, and 0.5 lL of each forward/reverse primer to a
ﬁnal reaction volume of 50 lL. PCR was performed with an initial
denaturation for 4 min at 94 C, followed by 25 cycles with dena-
turation for 1 min at 94 C, annealing for 30 s at 46 C and exten-
sion for 90 s at 70 C and ﬁnishing with a ﬁnal extension for
10 min at 70 C. The PCR products underwent electrophoresis on
a 1.2% agarose gel to analyze the expression level of the HER2 gene.
The primers used for HER2 were as follows: forward 50-GAG-
CACCCAAGTGTGCAC and reverse 50-TTGGTTGTGAGCGATGAG.
2.6. Cell cycle analysis
SK-BR-3 cells were seeded in 60 mm dishes at a density of
5  105 cells per dish. When the cells reached a conﬂuence of
80%, the cells were treated with the compounds at the concentra-
tions indicated in the ﬁgure legends. Subsequently, the cells were
washed with ice-cold PBS (pH 7.4) and harvested by centrifugation
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The ﬁxed cells were washed with PBS before incubation with
50 lg/mL of propidium iodide (Sigma, St. Louis, MO, USA) and
2.5 lg/mL of RNase (Sigma, St. Louis, MO, USA). Fluorescence was
measured with a Fluorescence-Activated Cell Sorting (FACS)-Cali-
ber ﬂow cytometer (BD Biosciences, Lakes, NJ, USA). At least
10,000 cells were measured for each sample.
2.7. Transcription reporter gene assay
HEK293T human kidney cells were seeded in 96 well micro-
plates at a density of 5  103 cells per well and incubated over-
night. Mammalian expression vectors encoding the activation
domain of ESX, which were fused to the GAL4 DNA-binding do-
main (amino acids 1–94), were co-transfected into HEK293T cells
at a range of concentrations for each individual compound with a
reporter plasmid, as previously described (Shimogawa et al.,
2004). The reporter plasmid of the IL2 promoter carried ﬁve
GAL4 binding sites that produced secreted alkaline phosphatase
(SEAP) in an amount proportional to the interaction between
GAL4-ESX and endogenous Sur2, which is a subunit of the human
mediator complex. After 12 h of treatment with each compound, a
40 lL aliquot of culture medium was incubated at 65 C for 3 h to
inactivate all of the endogenous enzymes except for the SEAP en-
zyme. The 4-methylumbelliferyl phosphate (MUP) solution, which
is a ﬂuorescent SEAP substrate, was added to each well and incu-
bated at 37 C for at least 3 h in the dark. After incubation, the SEAP
activity was measured with a Microplate Fluorescence Reader
(SpectraMAX GEMINI EM, Molecular Devices, Sunnyvale, CA,
USA) using an excitation wavelength of 360 nm and an emission
wavelength of 440 nm. To verify that the signal decrease was
caused by the compounds’ inhibitory activity against the ESX–
Sur2 interaction and not by cell death, 5 lL of WST-1 (Promega,
Madison, WI, USA) was added to each well of the remaining cell
culture after removal of the aliquot for the SEAP assay. This solu-
tion was incubated at 37 C for at least 2 h. After incubation, the
absorbance of each well was measured with an Automatic Elisa
Reader System (Bio-Rad 3550, Hercules, CA, USA) at a wavelength
of 450 nm.
2.8. Kinase inhibition assay
Kinase inhibitory activities of CHO10 were evaluated using the
Millipore kinase proﬁling services with HER1, HER4, IGF1R, MAPK1
and MAPK2 kinases, following the KinaseProﬁler Service Assay pro-
tocols. CHO10 was tested at ﬁnal concentrations of 5 and 10 lM,
respectively, according to the method reported previously (Kim
et al., 2012). The scintillation values from each replicate were cal-
culated as% inhibition of kinase activity versus control.
2.9. Tumor xenografts in nude mice
Single-cell suspensions (1  107 cells) of NCI-H460 (human
non-small cell lung carcinoma cells) or DLD-1 (human colorectal
adenocarcinoma cells) with 95% viability were injected subcuta-
neously into the hind legs of 5-week-old BALB/c athymic nude
mice (SLC Inc., Hamamatsu, Japan). One-hundred microliters was
injected in each mouse to avoid leakage, and a different site was
used for each injection. When the tumors reached a volume of
150–250 mm3, mice were randomly grouped as three mice per
group. The tumor volume was determined according to the for-
mula (L  l2)/2, by measuring the tumor length (L) and width (l)
with calipers (Kim et al., 2010). CHO10 was dissolved in polyethyl-
eneglycol 400 and administered ﬁve times intravenously in a vol-
ume of 50 lL (1 mg/kg in ﬁnal amount) at various sites around
the tumor. The ﬁve administrations were performed once every2 days during the entire treatment period. All protocols for the tu-
mor xenograft studies were approved by the Institutional Animal
Care and Use Committee of the Korea Institute of Radiological
and Medical Sciences.
2.10. Statistical analysis
In all of the experiments, the data are expressed as the
mean ± standard deviation, with each experiment performed in
triplicate. Comparison of the differences was conducted with an
unpaired, two-tailed Student’s t-test. The differences were consid-
ered statistically signiﬁcant when the p value was <0.05.3. Results
3.1. Dithiiranylmethyloxy azaxanthones (CHO10) inhibits ESX–Sur2
interaction
The ESX transcription factor activates HER2 by binding to both
the HER2 promoter and Sur2, followed by the recruitment of the
human mediator complex and expression of HER2. The expression
of HER2 can be decreased by inhibiting the interaction between the
activation domain of ESX and its coactivator Sur2 (Chang et al.,
1997; Asada et al., 2002). Previous experimental and clinical stud-
ies reported that HER2 overexpression contributes to the develop-
ment of TAM resistance in ER-positive cancers (Benz et al., 2993;
Chung et al., 2002). Therefore, we attempted to ﬁnd a molecule
that interferes with the ESX–Sur2 interaction to down-regulate
the expression of HER2. A transcriptional reporter gene assay
was utilized to screen for ESX–Sur2 interaction inhibitors by
co-transfecting an ESX plasmid that was fused with the GAL4
DNA-binding domain and a reporter plasmid of an IL2 promoter
that carried ﬁve GAL4 binding sites. The ﬂorescence intensity that
represented SEAP activity was inversely proportional to the inhib-
itory activity of the compounds against the ESX–Sur2 interaction.
Sixty-three compounds were screened at a ﬁnal concentration of
10 lM. Among them, the compound CHO10 exhibited a severe de-
crease of ﬂuorescence intensity, while CHO3 was ineffectual in
terms of inhibitory activity. We further measured their dose-
dependent inhibitory activity against the ESX–Sur2 interaction.
These compounds have no topoisomerase activity, as reported pre-
viously (Cho et al., 2010, 2009). As displayed in Fig. 1B, wrenchno-
lol and canertinib decreased the SEAP activity with better potency
than CHO10, while BMS5999626 did not demonstrate any inhibi-
tory activity. Wrenchnolol has previously been reported as an
inhibitor of the ESX–Sur2 interaction that leads to HER2 down-reg-
ulation (Shimogawa et al., 2004). Canertinib and BMS599626 are
pan-HER receptor tyrosine kinase inhibitors (TKIs) (Smaill et al.,
2000; Spector et al., 2007). We also checked the cell viability after
each compound treatment by following the method described in
the Materials and Methods to verify that the decrease of SEAP
activity was induced by inhibiting the ESX–Sur2 interaction and
not caused by compound toxicity-mediated cell death. The cyto-
toxicity of canertinib and wrenchnolol was observed at concentra-
tions as low as 3 lM. CHO3 and CHO10 showed a very mild toxicity
at 10 lM in HEK293T. Therefore, of the synthetic compounds,
CHO10 had the strongest ESX–Sur2 interaction inhibitory activity.
Treatment with 3 lM CHO10 showed inhibitory activity that was
comparable to canertinib.
3.2. CHO10 down-regulates HER2 expression and HER2-mediated
downstream signal
To determine whether the ESX–Sur2 interaction inhibitory
activity of the compounds would affect HER2 gene ampliﬁcation
Table 1
Kinase inhibitory activity of CHO10.
Kinase % Inhibitiona at
5 lM 10 lM
HER1 0 6
HER4 0 3
IGF1R 0 6
MAPK1 12 15
MAPK2 0 3
a The results of % inhibition of CHO10 represent the mean values from individual
duplicate experiments that were provided by the KinaseProﬁler Service Assay
(Millipore, USA).
J.M. Nam et al. / European Journal of Pharmaceutical Sciences 50 (2013) 181–190 185and protein expression, SK-BR-3, which is a HER2-positive breast
cancer cell line (Järvinen et al., 2000), was treated with the com-
pounds at 10 lM. CHO10 dramatically reduced HER2 gene ampliﬁ-
cation and protein expression after 16 h of treatment, as shown in
Fig. 1C. Canertinib also attenuated both HER2 gene ampliﬁcation
and protein expression to an extent similar to CHO10, which was
consistent with a previous report concerning canertinib-mediated
HER2 protein down-regulation in a HER2-overexpressing osteosar-
coma cell line, OS-187, using 5 lM canertinib (Hughes et al., 2006).
HER2 down-regulation by CHO10 blocked the Tyr1221/1222 phos-
phorylation of HER2 with a potency similar to canertinib in SK-BR-
3. Tyr1221/1222 is one of the major autophosphorylation sites in
HER2. Phosphorylation of this site causes coupling of HER2 to the
Ras-MAP kinase signal transduction pathway (Kwon et al., 1997).
CHO10 attenuated phospho-HER2 to an extent comparable to can-
ertinib, and the downstream signaling was blocked by the CHO10
treatment in SK-BR-3 cells, which was validated by the decreased
protein level of phospho-MAPK and phospho-Akt (Fig. 1D). To ver-
ify whether the attenuation of HER2, MAPK and Akt phosphoryla-
tions was caused by inhibition of the kinase activity of HER family(A) 
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nal cascades without inhibiting kinase activity.
3.3. CHO10 preferentially inhibits the proliferation of HER2-
overexpressing cancer cells
To assess the effects of CHO10 on cell proliferation, HER2-posi-
tive and -negative cells were treated with different concentrations
of CHO10 for 48 h. The growth of the tested cell lines was inhibited
in a dose-dependent manner. In particular, CHO10-mediated
growth inhibition was more potent in the AU-565, BT474 and
SK-BR-3 cell lines, which are all HER2-overexpressing breast can-
cer cells (Cho et al., 2010; Chrestensen et al., 2007). The growth
inhibition caused by a 5 lM treatment of CHO10 was 88.6% in
AU-565, 87.7% in BT474 and 87.1% in SK-BR-3; the growth inhibi-
tion of CHO10 was 65.0% in MCF-7, which is a breast cancer cell
line that expresses a basal level of HER2, and 40.2% in HEK293,
which is a HER2-negative human embryonic kidney cells
(Fig. 2A). Overall, these results suggest that CHO10 preferentially
suppresses the growth of HER2-overexpressing cancer cells.
3.4. CHO10 promotes apoptotic cell death in SK-BR-3, HER2-
overexpressing cancer cell
The percentage of apoptotic cells in the sub G1 peak of com-
pound-treated SK-BR-3 was analyzed by FACS. As displayed in
Fig. 2B, after the SK-BR-3 cells were treated with 10 lM of each
compound for 24 h, a greater number of CHO10-treated cells
(48.1%) started to undergo apoptosis than those treated with
CHO3 (29.8%) or canertinib (30.8%). CHO10 induced apoptosis in
the SK-BR-3 cells in a dose- and time-dependent manner, which
was detected by observing the increase of the sub G1 peak in
Fig. 2C and D. Cleaved PARP was used as a marker for apoptosis
and was measured by western blotting. CHO10 induced the corre-
sponding increase of the PARP cleavage more potently than CHO3
but less potently than canertinib (Fig. 2E).
3.5. CHO10 promotes cell death in caspase-3-independent manner
Caspase-3 cleavage was not detected in the SK-BR-3 cells when
they were treated with 10 lM CHO10 (Fig. 3A) for up to 8 h, even
though CHO10-induced PARP cleavage was observed (Fig. 2E). To
conﬁrm this observation, the viability of SK-BR-3 cells was mea-
sured after treatment with CHO10 at concentrations of 0, 1, 5,
10, 15 and 25 lM in the absence and presence of 2 lM z-VAD-FMK for 48 h. The CHO10-induced cell death was not prevented
by the use of the broad-spectrum caspase inhibitor z-VAD-FMK,
as shown in Fig. 3B.
3.6. CHO10 enhances the cell growth inhibitory activity of tamoxifen in
BT474 tamoxifen-resistant breast cancer cells
The combination of CHO10 and TAM exhibited greater inhibi-
tion of cell proliferation than TAM alone or the combination of
TAM and canertinib (Fig. 4) in BT474 cells. The breast cancer cell
line BT474 comprises ER-positive breast cancer cells and expresses
high levels of ampliﬁed in breast cancer I (AIB1) and HER2. Because
of these characteristics, BT474 is a perfect experimental model for
TAM-resistance in ER-positive breast cancer cells (Su et al., 2008).
Co-treatment of BT474 cells with CHO10 (1 lM) and TAM inhibited
cell growth more strongly than TAM alone, accounting for 16.1% to
84.3% growth inhibition when treated with 5 lM of TAM for 72 h.
This result suggests that the combination of CHO10 and TAM is
much more potent than TAM alone for inhibiting the growth of
TAM-resistant HER2-overexpressing breast cancer cells.
3.7. CHO10 shows anti-tumor effect in an in vivo xenograft system
After we observed the augmentation of in vitro TAM sensitivity
by CHO10 in HER2-overexpressing TAM-resistant breast cancer
cells, the in vivo anti-tumor effects of CHO10 were examined. SK-
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but no tumor growth was observed. Therefore, we attempted to
use two other HER2-positive cancer cell lines, which were the
DLD-1 colorectal adenocarcinoma cell line (Bunn et al., 2001) and
the NCI-H460 large cell lung cancer cell line (LaBonte et al.,
2011) to test the anti-tumor effect of CHO10 on in vivo xenograft
tumors. When the NCI-H460 or DLD-1 subcutaneously implanted
xenograft tumors reached a minimum of 250 mm3 (10 days after
cell injection), the mice were randomly grouped (three mice per
group) and treated with either the vehicle alone (control) or
1 mg/kg of CHO10 ﬁve times every 2 days. As shown in Fig. 5,
the tumor volumes for the subjects treated with CHO10 were sig-
niﬁcantly reduced in comparison to the untreated controls for both
NCI-H460 and DLD-1 cells. These results suggest that CHO10
exhibited excellent anti-tumor effects in the mouse xenograft
model.4. Discussion
HER2 overexpression is detected in the cells of many types of
tumors but is mainly found in breast, gastric, ovarian and lung can-
cers (Carpenter and Cohen, 1990; Scholl et al., 2001). This trait is a
problem in anticancer therapeutics for the following reasons: (1)
HER2 forms dimers with itself or with other HER family members
without ligand-binding. HER2 overexpression is the determinant in
the dimerization process (Tzahar et al., 1996). Homo- and hetero-
dimers of HER2 trigger tyrosine autophosphorylation and then
augment intracellular signaling cascades, leading to cell prolifera-
tion and tumorigenesis (Wolf-Yadlin et al., 2006). (2) HER2 overex-
pression reduces wild type p53 expression, which causes cancer
cells to become resistant to chemo- and radio-therapy (Zheng
et al., 2004). (3) HER2 overexpression induces resistance against
anticancer drugs including trastuzumab (HER2 extracellular do-
main-targeting monoclonal antibody (mAb)), lapatinib (EGFR/
HER2 dual TKI) and TAM (estrogen receptor antagonist) (Benz
et al., 1993; Chung et al., 2002; Valabrega et al., 2007). Therefore,
the down-regulation of HER2 expression can be a good strategy
in combination regimens with HER2-targeting anticancer drugs
or HER2-mediated resistance-inducing drugs. HER2 overexpres-
sion is achieved by an uncontrolled transcription rate when the
ESX transcription factor binds to both the HER2 promoter and
Sur2 (Chang et al., 1997; Asada et al., 2002). Dithiiranylmethyloxy
azaxanthone, CHO10, inhibited the ESX–Sur2 interaction in a dose-
dependent manner with a potency that was similar to 3 lM can-ertinib (Fig. 1A and B), which leads to a reduction of HER2 gene
ampliﬁcation and protein expression. The direct relationship be-
tween the HER2 oncogene and the HER2 protein was reported pre-
viously in a comprehensive study of the gene and its products (RNA
and protein) in a large number of human breast and ovarian can-
cers (Slamon et al., 1989). HER2 oncogene ampliﬁcation was suc-
cessfully measured via quantitative reverse transcription-PCR,
which demonstrated signiﬁcant increase in mRNA transcript levels
in HER2-overexpressing patients compared to normal and HER2-
negative patients (Savino et al., 2007). The sequence of eight amino
acids in Sur2 (SWIIELLE), which is the smallest binding core of Sur2
for ESX activation domain (Asada et al., 2003), was blasted and did
not match any known protein. Therefore, CHO10, which was se-
lected as an ESX–Sur2 interaction inhibitor using our system, is
likely to have selectivity over any other transcript. The inhibition
of CHO10 against HER2 gene transcript via interference of the
ESX–Sur2 interaction was clearly attributed to the decrease in
the HER2 protein. HER2 overexpression in tumors leads to consti-
tutive activation of HER2-mediated downstream MAPK and PI3K/
AKT signal cascades, as well as autocrine cell growth (Carpenter
and Cohen, 1990; Hynes and Lane, 2005). The CHO10-mediated
down-regulation of the HER2 expression prevented the Tyr1221/
1222 phosphorylation of HER2 and decreased the phosphorylation
of MAPK and AKT with a potency similar to 10 lM canertinib treat-
ment in SK-BR-3 cells (Fig. 1C and D).
Successful combination regimens of HER2 down-regulators
have been reported; a combination of cetuximab (anti-EGFR
mAb)/trastuzumab (anti-HER2 mAb) demonstrated a synergistic
effect on tumor growth inhibition in nude mice xenografted with
the human pancreatic carcinoma cell lines Capan-1 and BxPC-3.
This tumor inhibition was attributed to reductions of both EGFR
and HER expression and AKT phosphorylation (Larbouret et al.,
2012). Afatinib, an EGFR/HER2 dual TKI, efﬁciently inhibited the
growth of cetuximab-resistant cancer cells in vitro, while elrotinib,
which is an EGFR-speciﬁc TKI, showed no difference in efﬁcacy be-
tween the cetuximab-resistant and -sensitive cells. Afatinib when
combined with cetuximab in vivo, showed an additive growth
inhibitory effect in cetuximab-resistant xenografts, while no addi-
tional beneﬁts from adding afatinib to cetuximab were observed in
cetuximab-sensitive xenografts (Quesnelle and Grandis, 2011).
Other researchers have also suggested that reduction of the expres-
sion of HER2 and 611-CTF, which is a C-terminal fragmented HER2
containing intracellular and transmembrane domains, through
anti-autophosphorylation at Tyr1248 of HER2/611-CTF by the
EGFR/HER2 dual TKI may enhance the effect of the EGFR-targeting
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Xia et al., 2011). The reduction of HER2 expression when using a
HER2 mRNA-antisense oligonucleotide was observed to enhance
the anticancer activity of a combined doxorubicin treatment in
SK-BR-3, HER2-overexpressing breast cancer cells (Sun et al.,
2011). Some small molecules down-regulated HER2 expression,
in addition to TKIs (Järvinen et al., 2000; Valabrega et al., 2007;
Sun et al., 2011). Berberine (BBR), which is a natural alkaloid,
was reported to inhibit cell proliferation and induce apoptosis by
suppressing HER2 expression and the HER2-mediated PI3K/Akt
signaling pathway in HER2-overexpressing breast cancer cells,
such as SK-BR-3, BT474, and HER2-overexpressing MCF-7 (MCF-
7/HER2) cells (Kuo et al., 2011). The extent of the reduction of
phospho-HER2/phospho-Akt induced by BBR treatment (25 or
50 lM for 24 or 48 h) was stronger in SK-BR-3 cells than that in
BT474 and MCF-7/HER2 cell lines. Unlike BBR, CHO10 induced a
signiﬁcant decrease in the protein levels of phospho-HER2, phos-
pho-MAPK and phospho-Akt with a smaller amount (10 lM treat-
ment for 16 h) than BBR in SK-BR-3 cells (25 or 50 lM for 24 or
48 h). Luteolin, which is a naturally occurring ﬂavonoid, was
reported to effectively inhibit cell proliferation and induce apopto-
sis in HER2-overexpressing cancer cells, including AU565, MDA-
MB-453 and SKOV3.ip1 (Chiang et al., 2007). Luteolin considerably
reduced the level of the HER protein with a 20 or 40 lM treatment
for 24 h and preferentially inhibited the proliferation of HER2-
overexpressing cancer cells; a 20 lM luteolin treatment blocked
>60% of the growth in AU565, MDA-MB-453 and SKOV3.ip1 cells,
while it was much less effective in MCF-7 and HBL-100 cells that
expressed basal levels of HER2 under the same conditions. The
mechanism of the luteolin-mediated HER2 down-regulation is dif-
ferent from that of CHO10; luteolin promotes HER2 degradation
through dissociating HER2 from Hsp90 without signiﬁcantly
affecting the level of Hsp90. Although the mechanism of HER2
depletion is different from each other, both CHO10 and luteolin
are able to inhibit preferentially the proliferation of HER2-
overexpressing cancer cells (Fig. 2A) (Chiang et al., 2007). The
ESX–Sur2 interaction inhibitory activity of CHO10 led to the
down-regulation of HER2 and caused apoptosis in a dose- and
time-dependent manner, as demonstrated by the increase in sub
G1 population (Fig. 2C and D) and cleaved PARP level (Fig. 2E)
without caspase-3 activation (Fig. 3A and B). The mechanism
underlying caspase-independent cell death is very complex
(Donovan and Cotter, 2004). PARP can directly induce apoptosis
regardless of caspase-3 activation by stimulating the release of
apoptosis initiating factor (AIF), which translocates into the
nucleus (Yu et al., 2006). BBR was reported to induce apoptosis
by activating the mitochondria/caspase pathway in HER2-
overexpressing breast cancer SK-BR-3 cells (Kuo et al., 2011) and
was also reported to lead to colon tumor cell death through PARP
activation-dependent AIF activation without stimulating caspase
activation. The BBR-induced colon cell death was not affected by
co-treatment with a caspase inhibitor (Wang et al., 2012). Dasati-
nib, a small molecule tyrosine kinase inhibitor, exhibited
caspase-independent cell death in HER2-overexpressing breast
BT474 cells (Seoane et al., 2010). Dasatinib exhibited a synergistic
effect with trastuzumab on inducing apoptosis and DNA damage
without caspase activation but with a decrease in the levels of pro-
caspases. The caspase-3-independent mode of action of CHO10
against SK-BR-3 cells may require further study to be elucidated
clearly.
When HER2/HER3 signaling is decreased, which reduces Akt
signaling, TAM-resistance in ER-positive breast cancer cells is re-
duced (Lindberg et al., 2011; Ghayad et al., 2010). HER2 overex-
pression is one of the primary mechanisms underlying the
acquisition of TAM resistance (Ring and Dowsett, 2004; Bunone
et al., 1996; Benz et al., 1993; Chung et al., 2002). Therefore,CHO10 was evaluated for its ability to reverse TAM resistance in
BT474 cells. A combination of CHO10 (1 lM) and TAM enhanced
the growth inhibition of BT474 cells from 16.1% to 84.3% with a
5 lM TAM treatment (Fig. 4). This result is consistent with the
observation that the reduction of PAX2, which is required for the
active repression of HER2 in breast cancer, caused HER2-driven
TAM-resistant cell growth by using PAX2 siRNA (Hurtado et al.,
2008). A novel inhibitor that reduces HER2 expression and signal-
ing was also evaluated for the inhibition of TAM-resistant breast
cancer cell growth; chenodeoxycholic acid treatment reduced
HER2 expression and p42/44 MAPK phosphorylation in TAM-resis-
tant breast cancer cells via the inhibition of binding of the nuclear
factor-jB transcription factor with the HER2 promoter (Giordano
et al., 2011). Roscovitine, a 2,6,9-substituted purine analog, known
as a selective orally bioavailable CDK2 inhibitor, attenuated HER2
expression and ameliorated the MCF-7 HER2-deriven TAM-resis-
tant xenograft tumor (Meijer et al., 1997; Nair et al., 2011). The
anti-tumor activity of CHO10 was conﬁrmed by a study with xeno-
grafted mice; treatment with 1 mg/kg ﬁve times every 2 days sig-
niﬁcantly reduced HER2-positive NCI-H460 or DLD-1 cells
subcutaneously implanted xenograft tumors (Fig. 5) (Bunn et al.,
2001; LaBonte et al., 2011).
In conclusion, our data provide insight into the design of small
molecules that induce HER2 down-regulation by interfering with
the ESX–Sur2 interaction. Our study also afforded a rationale for
a strategy of combined endocrine therapy with a novel ESX–Sur2
interaction inhibitor, which is capable of reducing HER2 expression
and signaling, thereby inhibiting HER2-driven TAM-resistant can-
cer cell growth.
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